Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GC3106 in Healthy Adults
NCT02249221Phase 2Completed
- Sponsor
- GC Biopharma
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GC3106 in influenza, sponsored by GC Biopharma. Started Oct 2014; status: completed.
02
Drugs
GC3106
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02249221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249221.